Literature DB >> 12404072

Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.

James P Zacny1.   

Abstract

RATIONALE: The subjective, psychomotor, and physiological effects of prescription compounds containing the opioid hydrocodone have not been studied in a population of non-drug-abusing people who might be prescribed these compounds for cough or pain relief.
OBJECTIVES: To characterize the effects of a hydrocodone combination product, Hycodan, which contains hydrocodone and a peripherally-acting anticholinergic, homatropine, in non-drug-abusing volunteers.
METHODS: Eighteen volunteers participated in a crossover, double-blind study in which they received placebo; 5 mg hydrocodone/1.5 mg homatropine, 10 mg hydrocodone/3 mg homatropine, 20 mg hydrocodone/6 mg homatropine (all PO); 40 mg morphine (PO); and 2 mg lorazepam (PO). Measures were assessed before and for 300 min after drug administration. End-of-session and 24-h measures were taken to assess residual drug effects and overall subjects' assessment of the drug effects. RESULTS. Subjective effects of the hydrocodone/homatropine combination were dose-related, although the majority of statistically significant effects were limited to the highest dose combination tested. A combination of 20 mg hydrocodone/6 mg homatropine and morphine had a similar profile of subjective effects, which included both pleasant and unpleasant effects. Peak liking ratings were increased by 20 mg hydrocodone/6 mg homatropine and morphine, and trough ratings of liking (dislike) were lower in the 20 mg hydrocodone/6 mg homatropine condition, relative to the placebo condition. Post-session ratings of overall liking were not significant, either at the end of the session or 24 h later. Cognitive and psychomotor impairment were more marked with lorazepam than with hydrocodone/homatropine and morphine. Miosis and exophoria were increased in a dose-related manner by hydrocodone/homatropine.
CONCLUSIONS: Hycodan at the highest dose tested had effects similar to that of a prototypic mu agonist, morphine. Both drugs produced pleasant (including drug liking) as well as unpleasant subjective effects. Post-session ratings of overall liking and "want to take drug again" were not significant.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12404072     DOI: 10.1007/s00213-002-1245-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

Review 1.  Neuropsychological consequences of opiate use.

Authors:  Staci A Gruber; Marisa M Silveri; Deborah A Yurgelun-Todd
Journal:  Neuropsychol Rev       Date:  2007-08-10       Impact factor: 7.444

Review 2.  Sex, gender, and pain: an overview of a complex field.

Authors:  Robert W Hurley; Meredith C B Adams
Journal:  Anesth Analg       Date:  2008-07       Impact factor: 5.108

3.  An old drug for use in the prevention of sudden infant unexpected death due to vagal hypertonia.

Authors:  Pier Paolo Bassareo; Valentina Bassareo; Donatella Manca; Vassilios Fanos; Giuseppe Mercuro
Journal:  Eur J Pediatr       Date:  2011-08-04       Impact factor: 3.183

4.  The opioid rotation ratio of hydrocodone to strong opioids in cancer patients.

Authors:  Akhila Reddy; Sriram Yennurajalingam; Hem Desai; Suresh Reddy; Maxine de la Cruz; Jimin Wu; Diane Liu; Eden Mae Rodriguez; Jessica Waletich; Seong Hoon Shin; Vicki Gayle; Pritul Patel; Shalini Dalal; Marieberta Vidal; Kimberson Tanco; Joseph Arthur; Kimmie Tallie; Janet Williams; Julio Silvestre; Eduardo Bruera
Journal:  Oncologist       Date:  2014-10-23

Review 5.  Likeability and abuse liability of commonly prescribed opioids.

Authors:  Rachel Wightman; Jeanmarie Perrone; Ian Portelli; Lewis Nelson
Journal:  J Med Toxicol       Date:  2012-12

6.  Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: a randomized cross-over trial.

Authors:  Barth L Wilsey; Scott Fishman; Chin-Shang Li; Jeanna Storment; Anthony Albanese
Journal:  Pharmacol Biochem Behav       Date:  2009-08-04       Impact factor: 3.533

7.  Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.

Authors:  William W Stoops; Kevin W Hatton; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2010-07-28       Impact factor: 4.530

8.  The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.

Authors:  Sharon L Walsh; Paul A Nuzzo; Michelle R Lofwall; Joseph R Holtman
Journal:  Drug Alcohol Depend       Date:  2008-07-07       Impact factor: 4.492

9.  Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers.

Authors:  James P Zacny; Sandra Gutierrez
Journal:  Psychopharmacology (Berl)       Date:  2003-08-29       Impact factor: 4.530

10.  Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.

Authors:  Monique M Cherrier; John K Amory; Mary Ersek; Linda Risler; Danny D Shen
Journal:  J Pain       Date:  2009-09-02       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.